twitter-header (2)

Product Synopsis

Acute Market Reports, the leading business intelligence provider, has released its latest research, “”Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Dee Growth””, which provides insights into Systemic Psoriasis Therapeutics  in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by Acute Market Reports team of industry experts.

 Browse Full Report Visit –


 In 2014, the value of the Systemic Psoriasis Therapeutics  market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.

 Browse All Reports of This Category –

 Table of Contents

 1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

 2 Introduction 9

2.1 Symptoms 10

2.1.1 Skin Manifestations 10

2.1.2 Psychological Impact 10

2.2 Etiology, Co-morbidities and Risk Factors 10

2.2.1 Genetics 10

2.2.2 Psoriatic Arthritis 10

2.2.3 Mental Health Disorders 10

2.2.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 11

2.2.5 Infections 11

2.2.6 Köebner Phenomenon 11

2.2.7 Other Immune-Mediated Diseases 12

2.3 Pathophysiology 12

2.4 Diagnosis 12

2.5 Epidemiology 13

2.6 Treatment and Management 14

 Send An Enquiry –

 3 Marketed Products 18

3.1 Overview 18

3.2 Methotrexate-Based Products 18

3.3 Sandimmune/Neoral (cyclosporine/modified cyclosporin) – Novartis 19

3.4 Humira (adalimumab) – AbbVie 20

3.5 Enbrel (etanercept) – Amgen 22

3.6 Remicade (infliximab) – Janssen Biotech 24

3.7 Stelara (ustekinumab) – Janssen Biotech 25

3.8 Comparative Efficacy and Safety 27

 4 Psoriasis Market to 2021 – Pipeline Products 29

4.1 Overview 29

4.2 Overall Pipeline 29

4.3 Pipeline Analysis by Molecule Type 31

4.4 Pipeline Analysis by Molecular Target 32

4.5 Clinical Trials 34

4.5.1 Overall Failure Rate 34

4.5.2 Failure Rate by Molecule Type 35

4.5.3 Failure Rate by Molecular Target 36


 About –  Acute Market Reports :


Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

 Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.


 Contact Us :

Chris Paul


Office No 101, 1st Floor ,

Aditi Mall, Baner,

Pune, MH, 411045


Toll Free(US/CANADA): +1-855-455-8662

India: +91 7755981103

Email :

Website :